Nocturnal Blood Glucose and IGFBP-1 Changes in Type 1 Diabetes: Differences in the Dawn Phenomenon between Insulin Regimens

Abstract

Objective: Insulin-like growth factor binding protein-1 (IGFBP-1) is known to regulate the bioavailability of insulin-like growth factor (IGF) and the levels of IGFBP-1 are increased in the morning in patients with type 1 diabetes mellitus. We investigated the nocturnal fluctuations of glucose, IGFBP-1, and free IGF-1 levels with three insulin regimens.

Research Design and Methods: Forty-eight type 1 diabetes patients were divided into three groups according to their basal insulin therapy (continuous subcutaneous insulin infusion [CSII], insulin glargine, NPH insulin). Blood samples were obtained every 2 h between 2 300 h and 0700 h to measure plasma glucose, IGFBP-1 and free IGF-1 levels.

Results: The dawn phenomenon was more frequent with NPH (62.1%) than with glargine (16.6%, p<0.05) and CSII (14.3%, p<0.05). In the NPH group, the serum IGFBP-1 levels were markedly increased from 21.0±3.6 ng/ml at 2 300 h to 200.3±21.8 ng/ml at 0700 h and free IGF-1 levels were inversely decreased; these changes were partially suppressed in the CSII and glargine groups.

Conclusions: The use of insulin regimens that provide sufficient insulin levels in the early morning can suppress the dawn phenomenon, leading to improved glycemic control. The increase in circulating IGFBP-1 in the morning, as a result of waning of insulin action, lowers free IGF-1 levels and may cause insulin resistance.

Key words

insulin-like growth factor binding protein-1 - dawn phenomenon - type 1 diabetes mellitus

References

• 1 Dunger DB, Regan FM, Acerini CL. Childhood and adolescent diabetes.  Endocr Dev. 2005;  9 107-120
• 2 Frystyk J, Nyholm B, Skjaerbaek C. et al . The circulating IGF system and its relationship with 24 h glucose regulation and insulin sensitivity in healthy subjects.  Clin Endocrinol. 2003;  58 777-784
• 3 Hilding A, Brismar K, Degerblad M. et al . Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.  J Clin Endocrinol Metab. 1995;  80 2646-2652
• 4 Kobayashi K, Amemiya S, Sawanobori E. et al . Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM.  Diabetes Care. 1997;  20 1442-1447
• 5 Lang CH, Vary TC, Frost RA. Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis.  Endocrinology. 2003;  144 3922-3933
• 6 Inokuchi M, Hasegawa T, Anzo M. et al . Standardized centile curves of body mass index for Japanese children and adolescents based on the 1978–1981 national survey data.  Ann Hum Biol. 2006;  33 444-453
• 7 Le Floch JP, Lévy M, Mosnier-Pudar H. et al . Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).  Diabetes Care. 2009;  32 32-37
• 8 Lee PD, Giudice LC, Conover CA. et al . Insulin-like growth factor binding protein-1: Recent findings and new directions.  Proc Soc Exp Biol Med. 1997;  216 319-357
• 9 Perriello G, De Feo P, Torlone E. et al . Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning.  Diabetologia. 1990;  33 52-59
• 10 Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes.  Diabetes Care. 2002;  25 593-598
• 11 Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes.  Diabetes Care. 2008;  31 ((Suppl 2)) S140-S145
• 12 Rosenstock J, Park G, Zimmerman J. U. S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group . Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U. S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.  Diabetes Care. 2000;  23 1137-1142
• 13 Schmidt MI, Hadji-Georgopoulos A, Rendell M. et al . The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation.  Diabetes Care. 1981;  4 579-585
• 14 van Cauter E, Desir D, Decoster C. et al . Nocturnal decrease in glucose tolerance during constant glucose infusion.  J Clin Endocrinol Metab. 1989;  69 604-611

Correspondence